MAP2K7 and head and neck squamous cell carcinoma: To this end, a study to determine whether MEK/ERK inhibitors synergistically enhance the efficacy of other anticancer drugs on inhibition of cell proliferation in cisplatin-resistant HNSCC is forthcoming.